PFE vs. BMY, ZTS, ABBV, MRK, JNJ, SNY, ABT, VRTX, REGN, and NVS
Should you be buying Pfizer stock or one of its competitors? The main competitors of Pfizer include Bristol-Myers Squibb (BMY), Zoetis (ZTS), AbbVie (ABBV), Merck & Co., Inc. (MRK), Johnson & Johnson (JNJ), Sanofi (SNY), Abbott Laboratories (ABT), Vertex Pharmaceuticals (VRTX), Regeneron Pharmaceuticals (REGN), and Novartis (NVS). These companies are all part of the "pharmaceutical preparations" industry.
Bristol-Myers Squibb (NYSE:BMY) and Pfizer (NYSE:PFE) are both large-cap medical companies, but which is the superior business? We will compare the two companies based on the strength of their risk, analyst recommendations, valuation, profitability, community ranking, earnings, institutional ownership, media sentiment and dividends.
Bristol-Myers Squibb pays an annual dividend of $2.40 per share and has a dividend yield of 5.4%. Pfizer pays an annual dividend of $1.68 per share and has a dividend yield of 6.2%. Bristol-Myers Squibb pays out -77.4% of its earnings in the form of a dividend. Pfizer pays out 466.7% of its earnings in the form of a dividend, suggesting it may not have sufficient earnings to cover its dividend payment in the future. Pfizer has increased its dividend for 15 consecutive years. Pfizer is clearly the better dividend stock, given its higher yield and longer track record of dividend growth.
In the previous week, Bristol-Myers Squibb had 3 more articles in the media than Pfizer. MarketBeat recorded 85 mentions for Bristol-Myers Squibb and 82 mentions for Pfizer. Bristol-Myers Squibb's average media sentiment score of 0.52 beat Pfizer's score of 0.08 indicating that Pfizer is being referred to more favorably in the news media.
Bristol-Myers Squibb has a beta of 0.39, meaning that its share price is 61% less volatile than the S&P 500. Comparatively, Pfizer has a beta of 0.61, meaning that its share price is 39% less volatile than the S&P 500.
Bristol-Myers Squibb has higher earnings, but lower revenue than Pfizer. Bristol-Myers Squibb is trading at a lower price-to-earnings ratio than Pfizer, indicating that it is currently the more affordable of the two stocks.
76.4% of Bristol-Myers Squibb shares are held by institutional investors. Comparatively, 68.4% of Pfizer shares are held by institutional investors. 0.1% of Bristol-Myers Squibb shares are held by insiders. Comparatively, 0.1% of Pfizer shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.
Pfizer has a net margin of 3.62% compared to Pfizer's net margin of -13.50%. Bristol-Myers Squibb's return on equity of 10.88% beat Pfizer's return on equity.
Bristol-Myers Squibb presently has a consensus price target of $60.00, suggesting a potential upside of 35.75%. Pfizer has a consensus price target of $36.33, suggesting a potential upside of 33.73%. Given Pfizer's higher probable upside, analysts plainly believe Bristol-Myers Squibb is more favorable than Pfizer.
Pfizer received 410 more outperform votes than Bristol-Myers Squibb when rated by MarketBeat users. Likewise, 69.08% of users gave Pfizer an outperform vote while only 66.87% of users gave Bristol-Myers Squibb an outperform vote.
Summary
Pfizer beats Bristol-Myers Squibb on 15 of the 21 factors compared between the two stocks.
Get Pfizer News Delivered to You Automatically
Sign up to receive the latest news and ratings for PFE and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding PFE and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NYSE and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Related Companies and Tools
